EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+48.42%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$1.05B
AUM Growth
+$1.05B
(+41%)
Cap. Flow
+$108M
Cap. Flow
% of AUM
10.23%
Top 10 Holdings %
Top 10 Hldgs %
64.97%
Holding
54
New
17
Increased
9
Reduced
10
Closed
10
Top Buys
| 1 |
Arvinas
ARVN
|
$55M |
| 2 |
Assembly Biosciences
ASMB
|
$46.9M |
| 3 |
AnaptysBio
ANAB
|
$31.9M |
| 4 |
IPHA
Innate Pharma
IPHA
|
$29.3M |
| 5 |
Merus
MRUS
|
$21.9M |
Top Sells
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$69.3M |
| 2 |
argenx
ARGX
|
$52.8M |
| 3 |
Solid Biosciences
SLDB
|
$34.6M |
| 4 |
Sarepta Therapeutics
SRPT
|
$14.3M |
| 5 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
$9.1M |
Sector Composition
| 1 | Healthcare | 92.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $149M | 13.45% | 9,426,640 | – | – |
|
2
Xencor
XNCR
$580M
| $86M | 7.75% | 2,501,557 | – | – |
|
|
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $79.9M | 7.2% | 3,627,597 -335,381 | -8% | -$7.39M |
|
4
FibroGen
FGEN
$47.8M
| $64M | 5.77% | 1,492,221 +198,414 | +15% | +$8.51M |
|
5
Kura Oncology
KURA
$686M
| $58.3M | 5.26% | 4,241,953 +200,000 | +5% | +$2.75M |
|
6
Ironwood Pharmaceuticals
IRWD
$214M
| $58.2M | 5.24% | 4,371,408 -300,000 | -6% | -$3.99M |
|
|
7
Arvinas
ARVN
$568M
| $55M | 4.96% | +1,339,069 | New | +$55M |
|
|
8
Assembly Biosciences
ASMB
$190M
| $48.9M | 4.4% | 2,388,268 +2,291,668 | +2,372% | +$46.9M |
|
9
Neurogene
NGNE
$264M
| $48.2M | 4.35% | 3,915,880 +1,650,000 | +73% | +$20.3M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $37M | 3.33% | 2,154,845 -6,675 | -0.3% | -$115K |
|
|
PRVL
11
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $35.6M | 3.21% | 2,248,306 -144,250 | -6% | -$2.28M |
|
|
12
argenx
ARGX
$43.6B
| $32.4M | 2.92% | 202,117 -329,048 | -62% | -$52.8M |
|
|
13
AnaptysBio
ANAB
$569M
| $31.9M | 2.88% | +1,966,100 | New | +$31.9M |
|
|
IPHA
14
Innate Pharma
IPHA
$199M
| $29.3M | 2.64% | +4,545,454 | New | +$29.3M |
|
|
15
Merus
MRUS
$4.98B
| $24.2M | 2.18% | 1,718,200 +1,552,600 | +938% | +$21.9M |
|
|
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $22.9M | 2.07% | 1,481,411 | – | – |
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| $21.4M | 1.93% | +500,000 | New | +$21.4M |
|
|
CHMA
18
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $15.1M | 1.36% | 3,043,827 | – | – |
|
|
HARP
19
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $13.4M | 1.21% | 908,547 -554,876 | -38% | -$8.21M |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $12.5M | 1.13% | +173,364 | New | +$12.5M |
|
21
Ultragenyx Pharmaceutical
RARE
$2.89B
| $11.2M | 1.01% | 261,554 +200,000 | +325% | +$8.54M |
|
22
Cartesian Therapeutics
RNAC
$261M
| $10.9M | 0.99% | +4,597,701 | New | +$10.9M |
|
23
Exicure
XCUR
$35.4M
| $10.1M | 0.91% | 3,544,186 -1,971,039 | -36% | -$5.64M |
|
|
PVLA
24
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $9.18M | 0.83% | +2,535,212 | New | +$9.18M |
|
25
Fate Therapeutics
FATE
$120M
| $8.83M | 0.8% | +451,354 | New | +$8.83M |
|